| Téléchargement | - Voir la version finale : An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity (PDF, 1.3 Mio)
|
|---|
| DOI | Trouver le DOI : https://doi.org/10.1016/j.vaccine.2021.07.034 |
|---|
| Auteur | Rechercher : Fluckiger, Anne-CatherineIdentifiant ORCID : https://orcid.org/0000-0002-4139-0741; Rechercher : Ontsouka, Barthelemy; Rechercher : Bozic, Jasminka; Rechercher : Diress, Abebaw; Rechercher : Ahmed, Tanvir; Rechercher : Berthoud, Tamara; Rechercher : Tran, Anh1Identifiant ORCID : https://orcid.org/0000-0003-0644-6014; Rechercher : Duque, Diane1; Rechercher : Liao, Mingmin; Rechercher : McCluskie, Michael1; Rechercher : Diaz-Mitoma, Francisco; Rechercher : Anderson, David E.Identifiant ORCID : https://orcid.org/0000-0003-1350-9431; Rechercher : Soare, Catalina |
|---|
| Affiliation | - Conseil national de recherches du Canada. Thérapeutique en santé humaine
|
|---|
| Bailleur de fonds | Rechercher : ISED |
|---|
| Format | Texte, Article |
|---|
| Sujet | SARS-COV-2; vaccine; virus-like-particles; immunogenicity; neutralizing antibodies |
|---|
| Résumé | We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several adjuvants in an effort to identify a highly potent Coronavirus disease 2019 (COVID-19) vaccine candidate. eVLPs expressing a modified prefusion form of SARS-CoV-2 spike protein were selected as they induced high antibody binding titers and neutralizing activity after a single injection in mice. Formulation of SARS-CoV-2 S eVLPs with aluminum phosphate resulted in balanced induction of IgG2 and IgG1 isotypes and antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of this candidate, named VBI-2902a, protected Syrian golden hamsters from challenge with SARS-CoV-2 and supports the on-going clinical evaluation of VBI-2902a as a highly potent vaccine against COVID-19. |
|---|
| Date de publication | 2021-07-16 |
|---|
| Maison d’édition | Elsevier |
|---|
| Licence | |
|---|
| Dans | |
|---|
| Langue | anglais |
|---|
| Publications évaluées par des pairs | Oui |
|---|
| Identificateur | S0264410X21009117 |
|---|
| Exporter la notice | Exporter en format RIS |
|---|
| Signaler une correction | Signaler une correction (s'ouvre dans un nouvel onglet) |
|---|
| Identificateur de l’enregistrement | 8d80f04e-c26e-4ce5-b693-2e491570db49 |
|---|
| Enregistrement créé | 2022-09-06 |
|---|
| Enregistrement modifié | 2022-09-06 |
|---|
